Effects of sevoflurane or propofol on cancer malignancy in
ovarian cancer cells
Sevoflurane significantly increased the ovarian cancer cell viability of
compared to naïve control (NC vs . S, 100.0 ± 1.5 vs . 122.0
± 4.1, p < 0.0001, n = 6), while propofol significantly
decreased the cell viability (NC vs . S, 100.0 ± 1.5 vs .
61.6 ± 5.4, p < 0.0001, n = 6) (Fig 1A ). The
proliferation of SKOV3 cells was indicated by the number of Ki-67
positive cells (Fig 1B ). It was found that the number of Ki-67
positive cells was significantly increased by sevoflurane administration
(NC vs . S, 32.0 ± 5.1 vs . 52.4 ± 13.8, p < 0.01,
n = 6). However, Ki-67 positive cells were significantly decreased by
propofol treatment (NC vs . P, 32.0 ± 5.1 vs . 16.0 ± 7.3, p
< 0.05, n = 6) (Fig 1C ).
The migrate capability of ovarian cancer cells after sevoflurane
treatment was significantly greater than that of the naïve control (NCvs . S, 55.2 ± 7.5 vs . 92.5 ± 8.2, p < 0.0001, n
= 6) (Fig 1D ). In contrast, the migrate capability of cancer
cells was inhibited by propofol exposure (NC vs . P, 55.2 ± 7.5vs . 34.3 ± 9.4, p < 0.01, n = 6) (Fig 1E ). The
invasion of ovarian cancer cells was evaluated by comparing the number
of invasive cells with Transwell assay. Significantly higher number of
invasive cells was observed in the sevoflurane group compared to naïve
control (NC vs . S, 1.0 ± 0.1 vs . 2.2 ± 0.6, p <
0.0001, n = 6) (Fig 1F ), whereas propofol exhibited an opposite
effect (NC vs . P, 1.0 ± 0.1 vs . 0.4 ± 0.1, p <
0.05, n = 6) (Fig 1G ).